Pinebridge Investments L.P. Decreases Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Pinebridge Investments L.P. reduced its position in Hologic, Inc. (NASDAQ:HOLXGet Rating) by 19.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 232,180 shares of the medical equipment provider’s stock after selling 57,614 shares during the quarter. Pinebridge Investments L.P. owned approximately 0.09% of Hologic worth $17,776,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Geode Capital Management LLC grew its position in shares of Hologic by 0.4% in the third quarter. Geode Capital Management LLC now owns 5,391,428 shares of the medical equipment provider’s stock valued at $397,149,000 after purchasing an additional 20,373 shares in the last quarter. Parnassus Investments LLC grew its position in shares of Hologic by 0.7% in the third quarter. Parnassus Investments LLC now owns 4,142,799 shares of the medical equipment provider’s stock valued at $305,780,000 after purchasing an additional 26,894 shares in the last quarter. TD Asset Management Inc. grew its position in shares of Hologic by 78.9% in the fourth quarter. TD Asset Management Inc. now owns 2,656,184 shares of the medical equipment provider’s stock valued at $203,357,000 after purchasing an additional 1,171,229 shares in the last quarter. Barrow Hanley Mewhinney & Strauss LLC grew its position in shares of Hologic by 187.2% in the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 2,519,813 shares of the medical equipment provider’s stock valued at $185,987,000 after purchasing an additional 1,642,475 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Hologic by 6.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,199,084 shares of the medical equipment provider’s stock worth $168,362,000 after buying an additional 130,686 shares in the last quarter. Institutional investors own 92.70% of the company’s stock.

In other news, insider Sean S. Daugherty sold 2,179 shares of the business’s stock in a transaction dated Thursday, February 24th. The stock was sold at an average price of $71.14, for a total value of $155,014.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.54% of the company’s stock.

Several equities analysts recently commented on HOLX shares. Raymond James reduced their target price on Hologic from $88.00 to $84.00 and set an “outperform” rating for the company in a research report on Thursday, February 3rd. Morgan Stanley reduced their target price on Hologic from $76.00 to $75.00 and set an “equal weight” rating for the company in a research report on Thursday, February 3rd. Citigroup reduced their target price on Hologic from $78.00 to $75.00 in a research report on Thursday, April 28th. Wells Fargo & Company cut Hologic from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $90.00 to $75.00 in a research report on Monday, April 25th. Finally, StockNews.com started coverage on Hologic in a research report on Thursday, March 31st. They set a “buy” rating for the company. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $79.00.

HOLX stock traded up $0.37 during mid-day trading on Thursday, hitting $73.86. 46,182 shares of the stock were exchanged, compared to its average volume of 1,808,464. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.97 and a quick ratio of 2.57. The business has a fifty day moving average price of $74.48 and a 200 day moving average price of $73.40. Hologic, Inc. has a 12 month low of $60.10 and a 12 month high of $81.04. The stock has a market capitalization of $18.42 billion, a price-to-earnings ratio of 12.12, a PEG ratio of 0.87 and a beta of 1.09.

Hologic (NASDAQ:HOLXGet Rating) last issued its quarterly earnings results on Wednesday, April 27th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.55 by $0.52. Hologic had a return on equity of 42.26% and a net margin of 28.79%. The firm had revenue of $1.44 billion during the quarter, compared to analyst estimates of $1.28 billion. During the same quarter in the previous year, the company posted $2.59 earnings per share. As a group, equities analysts forecast that Hologic, Inc. will post 5.56 EPS for the current fiscal year.

Hologic Company Profile (Get Rating)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

Featured Articles

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.